-+ 0.00%
-+ 0.00%
-+ 0.00%

Editas Medicine To Present Data On LDL Cholesterol–Lowering In Vivo Crispr Gene Editing Medicine At American Heart Association Scientific Sessions

Benzinga·11/03/2025 14:10:07
Listen to the news

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana.